Picto_R&D Offers

Unlock Breakthrough R&D Opportunities and Connect with the Leukemia Experts!

Discover cutting-edge R&D partnering offers from over 40+ academic organizations, spanning everything from pioneering basic research to impactful real-world clinical studies. Whether you’re seeking collaboration or insights, this is your chance to engage directly with leading experts to propel innovation forward in the field of leukemias and related diseases.

As participant, you will use our event networking app to easily browse through 70+ exclusive R&D opportunities and set up personalized (1:1) meetings with the concerned leukemia experts.

Start exploring now!

FUNCTIONAL STUDIES
  • Role of PPAR-Y in hematopoiesis and the bone marrow environment: preclinical models and tests (myeloproliferative neoplasms)
  • Calcium signaling in acute myeloid leukemia
TARGET DISCOVERY
  • Studies of the mechanism of hematopoietic stem cell transformation in acute myeloid leukemia and clonal selection
  • Study of molecular mechanisms regulating normal and malignant hematopoiesis (AML)
  • Development of new targeted therapies for acute myeloid leukemia
DRUG DESIGN
  • Platform for accelerating the discovery and optimization of new bioactive molecules (acute leukemias)
PRECLINICAL DEVELOPMENT
  • Platform for developing and implementing tests for preclinical validation in vitro, ex vivo, and in vivo (acute leukemias)
  • Models for preclinical studies of the impact of bone marrow fibrosis on the natural history of hemopathies (myeloproliferative neoplasms)
  • In vitro evaluation of the effects of antileukemic drugs in a modeled leukemic niche with optimized bone marrow microenvironment (MSCS, hypoxia, pressure) (MPN/ALL/AML/MDS)
  • Platform for screening molecules able of reprogramming primary human macrophages (AML/myelofibrosis/MDS/CMML)
  • Platform for the isolation of organelles in leukemia cells to assess functional modulations linked to pathology or chemotherapeutic treatment (AML/MDS/CMML)
  • Characterization of cell death in leukemia cells to assess the efficacy of therapeutic solutions in the treatment of myeloid leukemia (AML/MDS/CMML)
  • In cellulo identification or validation of therapeutic targets in myeloid leukemia using click chemistry technology to develop new diagnostic methods or targeted therapies
  • Pharmacodynamic studies for the development of new treatments for acute myeloid leukemia
  • Preclinical mouse models for new molecules screening in the treatment of acute lymphoblastic leukemia b
  • Preclinical xenograft models for the evaluation of new compounds in the treatment of acute lymphoblastic leukemia b
  • Artificial intelligence-augmented cellular imaging in acute myeloid leukemia (diagnosis, prognosis, stratification)
  • Development of immunotherapies targeting the cytotoxic activity of NK cells (ALL/MDS)
  • In vivo model of waldenström disease
  • Study of immune cell biology in response to treatment in AML/MDS/WM patients
  • In vitro translational studies for the development of differentiating targeted therapies for acute myeloid leukemia
  • In vitro and in vivo models for studying the functional genetics of acute myeloid leukemia in children
  • Preclinical models for the development of new treatments for myeloproliferative neoplasia
  • Investigating the mechanism of action of drug candidates for the treatment of myelodysplastic syndromes and acute myeloid leukemia
  • Leukemic niche modeling (AML)
  • Platform for multiomic analysis of hematopoiesis or the immune system in patients with hematological malignancies or after csh allograft (ALL/AML/MPS/MDS)
  • Mouse models for the study of graft-versus-host disease (GVHD) or graft-versus leukemia (GVL) (ALL/AML)
  • Preclinical studies for the development of innovative treatments for acute lymphoblastic leukemia
  • Preclinical study of hematopoietic system regeneration following exposure to genotoxic stress such as irradiation and chemotherapy (ALL/AML)
  • Development of small molecules for targeted therapies (ALL/AML)
  • An integrative functional platform to tackle relapsed/refractory T-cell acute lymphoblastic leukemia
  • Preclinical mouse models for the development of new therapeutic treatments in B-cell acute lymphoblastic leukemia
  • Preclinical platform for chronic and advanced forms of myeloproliferative neoplasms
  • Translational studies to evaluate drug candidates for the treatment of chronic myeloid malignancies with a focus on chronic myelomonocytic leukemia (CMML) and other myelodysplastic/ myeloproliferative overlap neoplasms
  • Multi functional evaluation of AML and MDS
  • Preclinical murine models of aml for the evaluation of anti-leukemic molecules and immuno-therapies
  • Research of resistance mechanisms and identification of vulnerabilities in acute lymphoblastic (paediatric) and myeloblastic leukemia
BIOMARKERS
  • Rainbow platform: pharmacodynamic monitoring by single-cell omics
  • Specific transcriptomic expression profile predictive of early response to menin inhibitors in patients with relapsed/refractory acute myeloid leukemia
  • Atmospheric maps of environmental pollutants and evidence of their epigenetic effects on human bone marrow
BIOMARKERS / LEADS OPTIMIZATION /DRUG COMBINATION IDENTIFICATION
  • Next platform: drug combination screening of primary samples for acute myeloid leukemia
ATMP DEVELOPMENT
  • Clinical and preclinical evaluation of efficacy and toxicity of car-T cell (ALL/AML) treatments
  • Preclinical testing of car-T cells for the treatment of T/B acute lymphoblastic leukemia
CLINICAL DEVELOPMENT
  • National clinical research network for the design, sponsoring and conduct of phase I-IV interventional and non-interventional clinical trials (AML)
  • National clinical research network to support sponsors of phase I to IV interventional and non-interventional clinical trials (AML)
  • National clinical research network for the design, sponsoring and conduct of phase I-IV interventional and non-interventional clinical trials (CLL/WM/AML/MPS)
  • National clinical research network for the design, sponsoring and conduct of phase I-IV interventional and non-interventional clinical trials – collaboration (CLL/WM/AML/MPS)
  • National clinical research network for the design, sponsoring and conduct of phase II to IV interventional and non-interventional clinical trials (ALL)
  • National clinical research network for the design, sponsoring and conduct of phase I to III interventional and non-interventional clinical trials (MDS)
  • National clinical research network for the design and conduct of phase I-IV interventional and non-interventional clinical trials in childhood and adolescent leukemia (AML/ALL/MPS/MDS)
  • Cohort genomic annotation platform for phase I to III clinical trials (AML/MDS/leukemia predisposition syndromes)
  • Platform for genomic annotation and retrospective analysis of AML cohorts
  • Clinical investigation center for the sponsoring and conduct of phase I to III interventional clinical trials (ALL/AML/MPS/MDS)
  • Clinical investigation center for the coordination and conduct of phase I to III clinical trials in leukemia and related diseases (AML, MPS, MDS, ALL)
  • Clinical trials center for the design, sponsoring and conduct of phase I to IV interventional and non-interventional clinical trials in leukemia (CML, AML, ALL)
  • Metabolic, genomic, transcriptomic and functional analyses of the leukemic niche for phase 1 trials (MPN/ALL/AML/MDS)
  • Scientific national network for design and coordination of prospective clinical trials
  • Integrated chromosomal analysis platform: high-resolution analysis using optical genome mapping, karyotyping and fish for hematological malignancies
  • Immunophenotypic characterisation of dyserythropoiesis in myelodysplastic syndromes (MDS)
BIOMANUFACTURING
  • Manufacturing of advanced therapy drugs: early clinical trials of car-T cells (ALL/AML)
  • Manufacturing innovative therapy drugs: process optimization and industrialization (ALL/AML)
MEDICAL DIAGNOSTIC
  • Development of molecular diagnostics kits for genomic alteration in leukemia and other malignant hemopathies
COLLECTIONS / DATABASES
  • Data and samples from adult patients with acute myeloid leukemia (AML)
  • Clinical data and human-sample collection from patients with bone marrow failure (registre des insuffisances médullaires, RIME)
  • Hemodiag: a prospective cohort study of clinical and biological data for patients with hematologic malignancies
  • Clinico-biological data and bone marrow samples from patients (cells, DNA, RNA) with myelodysplastic neoplasms (MDS) and other hematological malignancies (AML/ALL, etc.)
  • Phase I-IV interventional and non-interventional clinical trial databases (MPN/CLL/WM/AML)
  • Real-life registry database study
  • Hematological malignancies biobank (CLL/AML)
  • Cryostem biobanking network expertise for hematology and cell therapy
EXPERT’S ADVICE
  • National clinical research network to support drug research and development (AML)
TRAINING
  • Educational events for bone marrow transplantation and cellular therapy
PROJECT MANAGEMENT
  • One stop shop for partnerships along the full leukemia therapeutics and diagnostic innovation and R&D value chain
ENTREPRENEURSHIP
  • Support for the creation and acceleration of startup companies in the field of leukemias and related diseases
Retour en haut